Cartesian Therapeutics, Inc. (RNAC)
(Delayed Data from NSDQ)
$13.75 USD
+0.38 (2.84%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $13.83 +0.08 (0.58%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Cartesian Therapeutics, Inc. (RNAC) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$41.60 | $45.00 | $39.00 | 211.14% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Cartesian Therapeutics, Inc. comes to $41.60. The forecasts range from a low of $39.00 to a high of $45.00. The average price target represents an increase of 211.14% from the last closing price of $13.37.
Analyst Price Targets (5 )
Broker Rating
Cartesian Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.43 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.50 a month ago based on six recommendations.
Of the seven recommendations deriving the current ABR, five are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 71.43% and 14.29% of all recommendations. A month ago, Strong Buy made up 66.67%, while Buy represented 16.67%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/RNAC.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 4 | 5 | 4 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.43 | 1.43 | 1.50 | 1.17 | 1.20 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/9/2024 | Needham & Company | Gil J Blum | Moderate Buy | Moderate Buy |
8/6/2024 | Cowen & Co. | Tyler Van Buren | Not Available | Strong Buy |
7/8/2024 | Mizuho SecuritiesUSA | Uy D Ear | Strong Buy | Strong Buy |
7/3/2024 | Canaccord Genuity | John L Newman | Strong Buy | Strong Buy |
7/2/2024 | Not Identified | Not Identified | Strong Buy | Hold |
6/17/2024 | H.C. Wainwright & Co. | Mitchell S Kapoor | Strong Buy | Strong Buy |
4/23/2024 | SVB Securities | Thomas J Smith | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.43 |
ABR (Last week) | 1.43 |
# of Recs in ABR | 7 |
Average Target Price | $41.60 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 253 |
Current Quarter EPS Est: | -0.78 |